methyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: methyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate
• 英文别名: methyl (1R,5S)-3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate
• 化学式: C₉H₁₃NO₃
• 分子量: 183.207
• InChiKey: RDUCFWUJNNWZLR-KNVOCYPGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate 在 tris-(dibenzylideneacetone)dipalladium(0) 、 三氟化硼乙醚 、 四乙基溴化铵 、 氢溴酸 、 potassium acetate 、 sodium hydride 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 为溶剂， 生成
  参考文献：
  名称：

  WO2020163405A5

  摘要：

  公开号：

  WO2020163405A5
• 作为产物：
  描述：

  1-(carbomethoxy)-2-acetonyl-5-methoxypyrrolidine 在 四氯化钛 、 苯基三氯硅烷 作用下， 以 二氯甲烷 为溶剂， 以58%的产率得到methyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate
  参考文献：
  名称：

  Mannich-Type Reaction of N,O-Acetals with Ketones Mediated by a Combination of TiCl4 and PhSiCl3

  摘要：

  A combination of TiCl4 and PhSiCl3 efficiently conducts the Mannich-type reaction of N,O-acetals with ketones to afford a-substituted cyclic amine derivatives in good yields. This method was applicable to preparation of azabicyclo compounds by the intramolecular Mannich-type reaction.

  DOI：

  10.3987/com-09-s(e)2

文献信息

• [EN] METABOTROPIC GLUTAMATE RECEPTOR MODULATORS<br/>[FR] MODULATEURS DE RÉCEPTEUR DE GLUTAMATE MÉTABOTROPIQUE
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2012152854A1

  公开（公告）日：2012-11-15

  The invention relates to heterocyclic derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

  该发明涉及杂环衍生物以及其药用可接受的盐。该发明还涉及制备这类化合物的方法。该发明的化合物是mGluR5调节剂，因此对于控制和预防急性和/或慢性神经系统疾病非常有用。
• OXIME-SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF
  申请人：Shionogi & Co., Ltd.

  公开号：US20140187544A1

  公开（公告）日：2014-07-03

  The present disclosure relates to Oxime-Substituted Quinoxaline-Type Piperidine Compounds, such as those of Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , R 20 , R 21 , Q, Y 1 , Z, A, B, and a are as defined herein; compositions comprising an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound.

  本公开涉及氧肟取代的喹喔啉型哌啶化合物，例如公式（I）中的化合物及其药用可接受的盐和溶剂化合物，其中R1、R2、R3、R4、R20、R21、Q、Y1、Z、A、B和a如本文所定义；包含有效量氧肟取代的喹喔啉型哌啶化合物的组合物，以及治疗或预防疾病的方法，例如疼痛，包括向需要治疗的动物施用有效量的氧肟取代的喹喔啉型哌啶化合物。
• ORGANIC COMPOUNDS
  申请人：Baeschlin Daniel Kaspar

  公开号：US20090281069A1

  公开（公告）日：2009-11-12

  The present invention relates to compounds of the formula; and their use in therapy.

  本发明涉及公式化合物及其在治疗中的应用。
• OXIME-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AS ORL-1 MODULATORS
  申请人：Purdue Pharma L.P.

  公开号：US20150238485A1

  公开（公告）日：2015-08-27

  The present disclosure relates to Oxime-Substituted Quinoxaline-Type Piperidine Compounds, such as those of Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , R 20 , R 21 , Q, Y 1 , Z, A, B, and a are as defined herein; compositions comprising an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound.

  本公开涉及肟取代的喹噁啉型哌啶化合物，例如式（I）中的化合物及其药学上可接受的盐和溶剂化合物，其中R1、R2、R3、R4、R20、R21、Q、Y1、Z、A、B和a如本文所定义；包含有效量肟取代的喹噁啉型哌啶化合物的组合物，以及治疗或预防疾病（如疼痛）的方法，包括向需要治疗的动物中有效量的肟取代的喹噁啉型哌啶化合物。
• Scaffold hopping approach towards various AFQ-056 analogs as potent metabotropic glutamate receptor 5 negative allosteric modulators
  作者：Holger Kubas、Udo Meyer、Mirko Hechenberger、Kai-Uwe Klein、Patrick Plitt、Ronalds Zemribo、Harm W. Spexgoor、Sander G.A. van Assema、Ulrich Abel

  DOI：10.1016/j.bmcl.2013.09.059

  日期：2013.12

  The metabotropic glutamate receptor subtype 5 has evolved into a promising target for the treatment of various diseases of the central nervous system, such as Fragile X and L-DOPA induced dyskinesia. One of the most advanced clinical compound is Novartis' AFQ-056 (Mavoglurant), which served us as a template for a scaffold hopping approach, generating a structurally diverse set of potent analogs. Both the limited aqueous solubility and the relatively poor metabolic stability of AFQ-056 were improved with hexahydrocyclopenta[c]pyrrole derivative 54a, which proved to be a valuable candidate for further development. (C) 2013 Elsevier Ltd. All rights reserved.